Articles by Rahul Banerjee, MD, FACP

Life After CAR T Therapy: Insights for Patients and Referring Oncologists
ByRahul Banerjee, MD, FACP ,Saad Z. Usmani, MD, MBA, FACP, FASCO,Binod Dhakal, MD ,Krystle Peterson, PA-C This video segment focuses on key elements of patient education and support for long-term CAR-T survivors, strategies to maintain quality of life and manage late effects, differences in supportive care needs between ide-cel and cilta-cel recipients, and approaches to fostering collaboration between academic centers and community practices for optimal long-term care.

Long-Term CAR-T Management in Myeloma: Collaborative Care and Monitoring Strategies for Patients Like Robert
ByRahul Banerjee, MD, FACP ,Saad Z. Usmani, MD, MBA, FACP, FASCO,Binod Dhakal, MD ,Krystle Peterson, PA-C This video segment examines protocols for long-term monitoring of CAR-T therapy patients, differences between academic and community settings, emerging adverse events, and strategies for multidisciplinary collaboration and care coordination to ensure seamless communication and continuity of care.

Getting to Know Robert, a 72-Year-Old Retired Teacher Facing a Myeloma Relapse and Considering CAR-T Therapy with Cilta-cel
ByRahul Banerjee, MD, FACP ,Saad Z. Usmani, MD, MBA, FACP, FASCO,Binod Dhakal, MD ,Krystle Peterson, PA-C This video segment profiles a 72-year-old retired science teacher with multiple myeloma, detailing his treatment journey from VRd induction and ASCT to relapse, management of comorbidities, and receiving cilta-cel, supported by his active and healthy wife.

QOL Considerations for Optimal Patient Outcomes with CAR-T Therapy
ByRahul Banerjee, MD, FACP ,Saad Z. Usmani, MD, MBA, FACP, FASCO,Binod Dhakal, MD ,Krystle Peterson, PA-C This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle support, balancing work during and after treatment, and effective supportive care measures.

Managing Neurotoxicities in CAR T: Clinical Approaches and Patient/Caregiver Education
ByRahul Banerjee, MD, FACP ,Saad Z. Usmani, MD, MBA, FACP, FASCO,Binod Dhakal, MD ,Krystle Peterson, PA-C This video segment explores the challenges of managing neurologic toxicities, including ICANS, in CAR-T therapy, highlighting monitoring strategies, tools for early detection, and approaches to communicating risks with patients and caregivers.

Managing Adverse Events with CAR T-Cell Therapy: Best Practices for Myeloma Care Teams
ByRahul Banerjee, MD, FACP ,Saad Z. Usmani, MD, MBA, FACP, FASCO,Binod Dhakal, MD ,Krystle Peterson, PA-C 
Meet Sarah, a 55-year-old Businesswoman With Multiple Myeloma Considering CAR-T Therapy With Ide-cel
ByRahul Banerjee, MD, FACP ,Saad Z. Usmani, MD, MBA, FACP, FASCO,Binod Dhakal, MD ,Krystle Peterson, PA-C